ROCHE MOCLOBEMIDE MAO-A INHIBITOR IS ANTIDEPRESSANT OUTLICENSE CANDIDATE FOR U.S. MARKET; REVERSIBLE, MAO-A SELECTIVE COMPOUND COULD AVOID DIET PROBLEMS